More than 3 Million Doses of Gadopiclenol Delivered by Bracco

Bracco’s gadopiclenol delivers effective contrast enhancement at half the gadolinium dose (0.05 mmol/kg) compared to other macrocyclic GBCAs - helping reduce cumulative Gd exposure without compromising diagnostic confidence. 

Three million doses administered worldwide mark an important milestone that confirms the trust of the medical community in a solution that combines safety, efficacy, and sustainability.

For more than 95 years, Bracco Group has been advancing standards of care in radiology. 

Our commitment extends far beyond delivering trusted contrast agents and is reflected in: 

• A broad portfolio and range of customer services that make us the radiology partner of choice

• Integrated clinical support and continuing education

• A focus on environmental sustainability and more conscientious use of gadolinium

• Strategic partnerships and continuous innovation since 1927, now supporting patients and radiology professionals in more than 100 countries